

DMS Pharmaceutical Group Named Hemofarm Agent

DMS Pharmaceutical Group Inc. has been named the **Hemofarm A.D. U.S. Agent**. Hemofarm, owned by **Stada Pharmaceuticals**, manufactures pharmaceutical goods in Vršac, Dubovac, Podgorica, Šabac, Banjaluka and the Russian city Obninsk. Stada representatives recently visited DMS Pharmaceutical Group, Inc. at their Park Ridge, Illinois location. DMS Pharmaceutical management team plans a visit to Stada Pharmaceutical's Germany location this summer to further its alliance with this company. 



From left, DMS executive vice president, **Bill Anderson**; Stada director, **Marcus Reinecker**; Stada vice president, **Dr. Matthias Wiedenfels**; DMS president, **Sam Lazich**.

Bayer HealthCare Sponsors Hemophilia Training Program

Bayer HealthCare Pharmaceuticals and the **World Federation of Hemophilia** (WFH) announced a three-year extension of Bayer's sponsorship agreement with WFH. The agreement calls for Bayer to serve as sole sponsor of WFH's International Hemophilia Training Centre (IHTC) program, in addition to providing support for other WFH activities, such as its Web site and Congress. Established in 1969, the IHTC program gives healthcare professionals from developing countries training in the diagnosis and management of hemophilia and related bleeding disorders.


Additionally, Bayer has made a major donation to WFH of Kogenate® FS,

antihemophilic factor (recombinant), a recombinant factor VIII treatment for hemophilia A, which will be used for humanitarian aid in countries where persons with hemophilia A have limited access to care. The donated Kogenate FS is commercially valued at more than \$7 million.

The IHTC program provides clinical, laboratory and paramedical training in 28 centers worldwide, located in the Americas, Africa and the Middle East, Asia, Western Pacific and Europe. Most recently, a new center was designated in Russia in 2010, and plans are underway to establish a center in Egypt.

"The International Hemophilia Training Centre program is critical to furthering the treatment of hemophilia

and related disorders around the world," said Claudia Black, WFH CEO. "We appreciate our long-standing partnership with Bayer, and commend the company on its commitment to the hemophilia community to help us achieve our vision of Treatment for All."

"More than 40 years after its founding, the IHTC program continues to improve the education of healthcare professionals who are dedicated to treating people with hemophilia," said Hansjoerg Duerr, vice president, Specialty Medicine, Bayer HealthCare Pharmaceuticals. "It is Bayer's privilege to sponsor an initiative of such great importance and also to make such a significant donation of Kogenate FS." 

Greenstone Introduces Two New Generic Products

Greenstone LLC, the generic pharmaceutical subsidiary of **Pfizer Inc.**, recently announced the introduction of EXEMESTANE tablets to its generic pharmaceutical product line.

EXEMESTANE is the authorized generic of Aromasin®. This new generic product is being offered in 25 mg tablets, available in bottles of 30 tablets.

Greenstone also announced the introduction of LATANOPROST, which

is the generic of, and thereby fully substitutable for, Xalatan®. This product is being offered in 125MCG/2.5 ML Solution, available in single count and three count cartons.

Both EXEMESTANE and LATANOPROST, which complement the growing line of products from Greenstone, are supported by a company heritage of commitment to quality, reliable manufacturing, and customer-focused attention. 